Evaluation of melanogenesis in A-375 melanoma cells treated with 5,7-dimethoxycoumarin and valproic acid
- PMID: 23001511
- PMCID: PMC6275710
- DOI: 10.2478/s11658-012-0033-4
Evaluation of melanogenesis in A-375 melanoma cells treated with 5,7-dimethoxycoumarin and valproic acid
Abstract
Malignant melanoma (melanoma malignum) is one of the most dangerous types of tumor. It is very difficult to cure. In recent years, a lot of attention has been given to chemoprevention. This method uses natural and synthetic compounds to interfere with and inhibit the process of carcinogenesis. In this study, a new treatment strategy was proposed consisting of a combination of 5,7-dimethoxycoumarin (DMC), an activator of melanogenesis, and valproic acid (VPA), a well-known drug that is one of the histone deacetylase inhibitors (HDACis). In conjunction with 1 mM VPA, all of the tested concentrations of DMC (10-150 μM) significantly decreased the proliferation of A-375 cells. VPA and DMC also induced the synthesis of melanin and the formation of dendrite and star-shaped cells. Tyrosinase gene expression and tyrosinase activity significantly increased in response to VPA treatment. Pyrolysis with gas chromatography and mass spectrometry (Py-GC/MS) was used to investigate the structure of the isolated melanin. This showed that the quantitative and qualitative components of melanin degradation products are dependent on the type of applied melanogenesis inductor. Products derived from eumelanin were detected in the pyrolytic profile of melanin isolated from A-375 cells stimulated with DMC. Thermal degradation of melanin isolated from melanoma cells after exposure to VPA or a mixture of VPA and DMC revealed the additional presence of products derived from pheomelanin.
References
-
- Davies M.A., Fox P.S., Papadopoulos N.E., Bedikian A.Y., Hwu W.J., Lazar A.J., Prieto V.G., Culotta K.S., Madden T.L., Xu Q., Huang S., Deng W., Ng C.S., Gupta S., Liu W., Dancey J.E., Wright J.J., Bassett R.L., Hwu P., Kim K.B. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin. Cancer Res. 2012;18:1120–1128. doi: 10.1158/1078-0432.CCR-11-2436. - DOI - PMC - PubMed
-
- Hoshimoto S., Faries M.B., Morton D.L., Shingai T., Kuo C., Wang H.J., Elashoff R., Mozzillo N., Kelley M.C., Thompson J.F., Lee J.E., Hoon D.S. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann. Surg. 2012;255:357–362. doi: 10.1097/SLA.0b013e3182380f56. - DOI - PMC - PubMed
-
- Hamid O., Schmidt H., Nissan A., Ridolfi L., Aamdal S., Hansson J., Guida M., Hyams D.M., Gómez H., Bastholt L., Chasalow S.D., Berman D. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 2011;9:204. doi: 10.1186/1479-5876-9-204. - DOI - PMC - PubMed
-
- Chodurek E., Orchel A., Gawlik N., Kulczycka A., Gruchlik A., Dzierzewicz Z. Proliferation and cellular death of A375 cell line in the presence of HDACs inhibitors. Acta Pol. Pharm. 2010;67:686–689. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous